FDA Removes Black-Box Warnings from Three Menopause Estrogen Patches, Bypassing Advisers Again

The US Food and Drug Administration (FDA) announced on Friday that three additional estrogen patches for menopause will no longer carry black-box warnings about cardiovascular disease, breast cancer, and dementia. This action follows the removal of similar warnings from six menopause treatments in February, bringing the total to nine products affected. The agency did not convene an advisory committee, and officials offered limited scientific justification during the press briefing, prompting concern among experts about a lack of transparency. The decision comes amid ongoing shortages of menopause patches across the United States, which may have influenced the regulatory move. Black-box warnings are the FDA's strongest safety alert, and their removal could alter prescribing practices and patient perceptions of risk. While some clinicians argue that modern low-dose transdermal estrogen carries lower risks than older oral formulations, others stress the need for rigorous evidence and public deliberation. The FDA's repeated bypass of its advisory process raises questions about how the agency balances drug safety, patient access, and scientific scrutiny. As demand for menopause treatments grows, the long-term impact of these regulatory changes on women's health remains to be seen.